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Abstract
The Ras-like GTPase Rheb has been identified as a crucial activator of mTORC1. Activation most likely requires a
direct interaction between Rheb and mTOR, but the exact mechanism remains unclear. Using a panel of Rheb-
deficient mouse embryonic fibroblasts (MEFs), we show that Rheb is indeed essential for the rapid increase of
mTORC1 activity following stimulation with insulin or amino acids. However, mTORC1 activity is less severely
reduced in Rheb-deficient MEFs in the continuous presence of serum or upon stimulation with serum. This remaining
mTORC1 activity is blocked by depleting the cells for amino acids or imposing energy stress. In addition, MEK
inhibitors and the RSK-inhibitor BI-D1870 interfere in mTORC1 activity, suggesting that RSK acts as a bypass for
Rheb in activating mTORC1. Finally, we show that this rapamycin-sensitive, Rheb-independent mTORC1 activity is
important for cell cycle progression. In conclusion, whereas rapid adaptation in mTORC1 activity requires Rheb, a
second Rheb-independent activation mechanism exists that contributes to cell cycle progression.
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Introduction
The mTORC1 complex plays a vital role in adapting cellular
metabolism of mammalian organisms to changing conditions
like progress through development, food intake, prolonged
starvation or acute stress (reviewed in 1). Information about the
availability of nutrients and growth factors is integrated by
various proteins present in mTORC1 and transmitted via the
kinase activity of mTOR (reviewed in 2). In mammalian cells,
two functionally distinct protein complexes, mTORC1 and
mTORC2, exist that share mTOR and LST8 as subunits.
Raptor and PRAS40 are unique for mTORC1. The best-studied
mTORC1 substrates are p70 S6 kinase1 (S6K) and 4E-BP1.
S6K is activated upon phosphorylation by mTORC1 and its
activity is crucial for cell growth. 4E-BPs inhibit translation
(reviewed in 3) and proliferation by binding to the eukaryotic
initiation factor eIF4E. mTORC1-mediated phosphorylation
leads to a release of 4E-BP from eIF4E, overcoming this
inhibition [3,4].
Multiple inputs emanating from various signaling pathways
underlie the complex upstream regulation of mTORC1. The
Ras-like GTPase Rheb is, when GTP-bound, a strong activator
of mTORC1 [5,6]. This GTPase is under the negative control of
the heterodimeric tumor suppressor complex TSC1/TSC2.
TSC2 harbors a GTPase activating protein (GAP) domain that
normally drives Rheb into the inactive GDP-bound state. Insulin
receptor signaling downregulates TSC2 GAP-activity via direct
phosphorylation of TSC2 by the phospatidylinositol-3-
phosphate dependent kinase PKB [7,8]. Other kinases like
ERK and RSK have also been shown to phosphorylate and
thereby negatively regulate TSC2 [1]. Conversely, when energy
supplies are limited a rise in AMP levels will activate the kinase
AMPK that increases TSC2 activity [9]. The importance of
TSC1/TSC2 in the control of mTORC1 is revealed in tuberous
sclerosis patients, where functional loss of either TSC1 or
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TSC2 results in non-metastatic tumors (reviewed in 10).
Indeed, in cells lacking TSC2 the fraction of GTP-bound Rheb
is very high [11], which leads to constitutive mTORC1 activity.
Raptor in the mTORC1 complex functions as a scaffold
protein that by binding to so-called TOS-motifs in substrates
like S6K and 4E-BP1 enhances their phosphorylation by
mTORC1 [12]. A regulatory function for Raptor has also been
suggested [13]. For example, TSC2 deficient cells remain
sensitive to energy stress via phosphorylation of Raptor by
AMPK, which inhibits mTORC1 [14]. Phosphorylation of Raptor
at multiple, different residues by RSK [15] or ERK [16] on the
other hand has been shown to positively regulate mTORC1.
For ERK, these sites include S863 that acts like a priming site
required for further phosphorylation of Raptor. However, this
site has also been reported as a direct mTOR-phosphorylation
site, indicating that mTOR, once activated, may influence the
activity of the complex in which it resides [17,18]. PRAS40 is
another mTORC1 complex member that has been proposed to
act as a negative regulator of mTORC1 via binding to Raptor
[19,20]. Release of PRAS40 is thought to be a two-step
process, in which PRAS40 is first phosphorylated by PKB at
S246 and then by mTORC1 at S183. Release of PRAS40
makes the TOS-binding motif in Raptor available for other
substrates [21].
Apart from post-translational control, mTORC1 is also
regulated by its subcellular localization. Depriving cells of
amino acids interferes in insulin-induced mTORC1 activity even
though more upstream components of the insulin signaling
pathway are activated normally [22]. Since elevated mTORC1
activity in TSC2 knockout cells can also be suppressed by
amino acid starvation, a TSC2-independent amino acid-
sensing mechanism was postulated [23]. This mechanism was
shown to involve the dimeric Rag GTPases (RagA/B and
RagC/D) [24,25]. RagA/B is GTP-loaded in amino acid replete
cells and targets the mTORC1 complex to lysosomes, where
Rheb is located.
Despite its high level of conservation during evolution [26]
species-specific functions for the mTOR pathway have been
uncovered (reviewed in 27). Furthermore, genetic studies using
conditional knockout mice demonstrate tissue-specific roles for
the mTOR pathway [28] [29] [30]. A functional mTOR pathway
is crucial for normal development, since targeted disruption of
either mTOR or Raptor in mice results in early embryonic
lethality [31] [32] [33]. It was therefore surprising that the
phenotype of mice lacking Rheb was much milder compared to
that of mice mutant for Raptor or mTOR [34] [35]. Here we set
out to address the question if mTORC1 would still be active in
the absence of Rheb using a panel of MEFs. The results
demonstrate that while Rheb is required for the strong insulin
and amino acid-induced mTORC1 activity, residual mTORC1
activity in Rheb-deficient cells is present, which is still subject
to negative regulation by energy stress and amino acid
withdrawal. This Rheb-independent mTORC1 activity helps to
drive cell proliferation in a rapamycin-sensitive fashion.
Results
We recently reported that genetic disruption of the Rheb
results in embryonic lethality around day 12 [34]. Since this
phenotype is much milder than that of mTOR or Raptor
deletion, this result suggested that mTORC1 is active in the
absence of Rheb or alternatively, that other signaling pathways
can substitute for mTORC1. Therefore, we generated MEFs
lacking Rheb. Spontaneously immortalized MEFs derived from
a conditional Rheb knockout mouse in which exon 3 is
surrounded by lox-sites [34] were infected with increasing
amounts of Cre adenovirus. Four days after infection cells had
strongly decreased levels of Rheb (Figure S1a). Subcloning of
Ad-CRE-infected cells yielded both Rheb-deficient cell lines
(e.g. N21, N23) and cells that had retained Rheb (e.g. N45,
N46). Genomic analysis (Figure 1a), Q-PCR (Figure 1b, Figure
S1b and S1c) and Western blotting (Figure 1c and d)
demonstrated the complete absence of functional Rheb.
Analysis of protein levels of various elements from the mTOR
pathway did not reveal significant differences (Figure S1d).
Furthermore, in cells growing in serum mTOR was localized on
LAMP1-positive vesicles as detected by immunofluorescence
(Figure S2a and S2b), while Rheb was found diffusely in the
cytoplasm (Figure S2c). As expected, insulin stimulation of
Rheb-deficient cells that had been serum starved only
marginally activated mTORC1 as determined by probing cell
lysates for phosphorylation of T389 of S6K, which is a direct
target for mTORC1 (Figure 1c, compare lane 2 and 5 with 8).
Similarly, mTORC1 in Rheb-deficient cells was virtually
irresponsive to replenishment of amino acids following amino
acid deprivation. Probing the same lysates for phosphorylation
of S6, the downstream target of S6K, confirmed that loss of
Rheb almost completely abolished insulin and amino acid-
induced S6K activity. As expected, Rheb containing cells
showed a strong enhancement of S6K activity in both
situations. mTORC2 was normally activated by insulin in Rheb-
deficient cells as judged from S473 phosphorylation of PKB.
Under serum starved conditions the level of S473 was elevated
as compared to Rheb-containing MEFs, most likely resulting
from a lower level of negative feedback from S6K to IRS1 [36].
The localization of mTOR on LAMP1-positive vesicles was not
severely affected by serum starvation or insulin stimulation, but
appeared slightly more diffuse in amino-acid starved cells
compared to cells stimulated with amino acids as has been
reported [25] (Figure S2d and S2e). These results are in line
with the documented role of Rheb in activating mTORC1 upon
stimulation of cells with insulin or amino acids.
Strikingly, we noticed that in Rheb-deficient cells grown in
the presence of serum T389 phosphorylation of S6K was
readily detectable, albeit at a lower level than in wild type cells
(Figure 1f, compare lane 8 with 2 and 5). To test if this reflected
mTORC1 activity, cells were treated with the ATP-competitive
TOR inhibitor PP242 or with the mTORC1 inhibitor rapamycin
(see Figure 1e for an overview of the mTORC1 pathway and
inhibitors used in this study). As can be seen in Figure 1e, both
inhibitors efficiently downregulated phospho-T389 levels
(compare lane 1 with 2-5 and lane 6 to 7-10), while only PP242
affected PKB phosphorylation at S473 via inhibition of
mTORC1 Activity in Rheb-Deficient MEFs
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Figure 1.  Characterization of Rheb-deficient cells (N21, N23) or control cells (N46, N45).  1a. PCR on decreasing amounts of
genomic DNA isolated from N46 cells (Rheb+/-), in which exon 3 from a single allele has been excised and N23 cells (Rheb-/-), in
which exon 3 from both Rheb alleles have been removed. In the positive control lane (+) a mixture of DNA isolated from wild type
animals, animals carrying the loxP sites surrounding exon 3 and Rheb-deficient embryos was used. In the negative control lane (-)
no input DNA was used. 1b. Q-PCR on mRNA isolated from Rheb-positive (N45; first and third bar) and Rheb-deficient (N23;
second and fourth bar) cells using primers from exon 2 and 3 (first and second bar) or from exon 2 and 5 (third and fourth bar). 1c.
Analysis of mTORC1 activity in total lysates by Western blotting. Cells were serum starved overnight. and left untreated, stimulated
with insulin for 30 minutes (Ins) or depleted for amino acids for two hours and then replenished with amino acids for 30 minutes
(AA). Blots were probed with antibodies indicated on the right. The upper three panels represent reprobes of the same blot. GAPDH
and Rap1 were used as loading controls. The immunoblots shown are representative for at least four experiments. Numbers on top
of immunoblots indicate ratio Rap1 over pS6K T389. 1d. Cells were serum starved overnight. and left untreated, stimulated with
insulin for 30 minutes (Ins) or with serum. The immunoblots shown are representative of observations for at least two experiments.
Rap1 was used as loading control. Numbers on top of immunoblots indicate ratio Rap1 over pS6K T389. 1e. Overview of the PI3K
and ERK pathway components converging on mTORC1 and indication of the inhibitors and stimuli used in this study. Arrows
represent activation, squares indicate inhibition. 1f. Asynchronously growing cells were either left untreated or treated with various
concentrations of PP242 (2, 1 or 0.25 µM) or rapamycin (50 nM) for 60 minutes. Total cell lysates were probed with antibodies
indicated on the right. The immunoblots shown are representative for at least two experiments. GAPDH was used as loading
control. Numbers on top of immunoblots indicate the ratio of pS6K T389 relative to GAPDH.
doi: 10.1371/journal.pone.0081649.g001
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mTORC2. To see if other direct mTOR substrates were also
phosphorylated in Rheb-deficient cells, we probed for
phosphorylation of PRAS40 at S183. The levels of S183
PRAS40 phosphorylation correlated with those of S6K and
were also clearly decreased by PP242 and rapamycin.
PRAS40 levels were equal in Rheb-positive and -negative
cells.
The marked degree of S6K phosphorylation in Rheb-
deficient cell lines grown in serum prompted us to further
investigate regulation of mTOR by serum. Therefore, we
compared phosphorylation of S6 following insulin or serum
stimulation of cells that had been starved of serum overnight.
S6K activity was enhanced in both cell types following serum
stimulation, although less pronounced in Rheb-deficient cells.
In agreement with the data presented above, insulin stimulation
only resulted in a significant increase in phosphorylation of S6
in wild type cells, while almost no effect was seen in Rheb-
negative cells (Figure 1d). Thus, mTORC1 is still active in
Rheb-deficient cells when grown in the continuous presence of
serum or when stimulated with serum.
To further substantiate that S6K phosphorylation in Rheb-
deficient cells requires mTORC1 activity, we knocked down
Raptor by RNAi. Indeed, a clear decrease in serum-induced
S6K phosphorylation was seen in Rheb-deficient cells (Figure
2a, compare lane 3 with 4). Another hallmark of mTORC1
activity is inhibition by energy stress via activation of AMPK
and subsequent phosphorylation of Raptor on S722 and S792
[14]. Therefore, cells were treated with phenformin or AICAR to
activate AMPK. Both agents efficiently blocked T389
phosphorylation of S6K in asynchronously growing MEFs
(Figure S3a, compare lane 1 with 2-3 and lane 5 with 6-7). Also
osmotic stress induced by addition of sorbitol, completely
abolished mTORC1 activity (compare lane 1 with 4 and 5 with
8). All three compounds clearly activated AMPK as judged from
phosphorylation of S172 and induced phosphorylation of
Raptor on S792.
One obvious explanation for the residual mTORC1 activity in
Rheb-deficient fibroblast would be the presence of RhebL1.
This protein is highly similar to Rheb, but has a much more
restricted expression pattern. Although there are no indications
from the literature that suggest that RhebL1 would selectively
respond to serum and not to insulin, we decided to knock down
RhebL1. Knock down of RhebL1 using siRNA did not affect
S6K activity (Figure S3b, lane 1 versus 2-3). Since efforts to
detect endogenous RhebL1 protein in MEFs using commercial
antibodies were unsuccessful, Q-PCR was used to judge the
efficacy of RNAi (Figure S3c). As an alternative, we knocked
down TSC2 that has been reported to act on RhebL1 [37] to
see if this would lead to an increased S6K phosphorylation.
While T389 phosphorylation of S6K is enhanced by TSC2
knock-down in control cells (Figure 2b, lane 5 versus 6), no
such effect is seen in Rheb-deficient cell lines (lane 1 versus 2
and lane 3 versus 4). Together, these data further underscore
that S6K phosphorylation in Rheb-deficient cells is mTORC1
dependent and sensitive to known negatively regulatory inputs
other than TSC2. To see if a similar Rheb-independent level of
mTORC1 activity could be detected in other asynchronously
growing cells, we performed Rheb and RhebL1 knockdown
Figure 2.  Western blot analysis of total lysates from Rheb-deficient cells (N21) and control cells (N45).  2a. Cells treated
with scrambled siRNA (-) or siRNA oligo’s directed against Raptor (+) were serum starved overnight (SS) or stimulated with serum
for 90 minutes (S). Western blots were probed with the antibodies indicated on the right. A representative example of one out of two
experiments is shown. Numbers on top of immunoblots indicate the ratio of pS6K T389 relative to GAPDH.. 2b. Control (N45) and
Rheb-deficient fibroblasts (N21, N23) were transfected with scrambled siRNA oligo’s or siRNA targeting TSC2. Total lysates of cells
in the presence of serum were analyzed by Western blotting with the antibodies indicated on the right. The immunoblots shown are
representative of observations for at least two experiments. Numbers on top of immunoblots indicate ratio pS6K T389 in cells with
TSC2 RNAi relative to control.
doi: 10.1371/journal.pone.0081649.g002
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experiments in A549 cells (Figure S3d). Despite an efficient
knockdown of Rheb, which led to a reduction in
phosphorylation of S6K T389 following insulin stimulation (lane
2 versus 4), a much less pronounced effect was seen in
asynchronously growing cells (lane 7 versus 8). Additional
knockdown of RhebL1 did not further decrease S6K
phosphorylation (lane 6 and 9). These results support the idea
that mTORC1 activity is partially Rheb-independent.
4E-BP1 is another established mTOR target, which inhibits
translation via its well-documented binding to eIF4E. 4E-BP1 is
phosphorylated by mTOR at T37 and T46. However, in order to
release 4E-BP1 from eIF4E-binding phosphorylation of
additional sites by mTOR is required, most notably S65 and
T70. The differentially phosphorylated isoforms of 4E-BP1 can
readily be separated by SDS-PAGE and analyzed with
phosphosite-specific antibodies. In asynchronously growing
control cells 4E-BP1 appeared as a doublet of which the
highest band was most intense (Figure 3a, lane 6). In Rheb-
deficient cells 4E-BP1 antibodies recognized three distinct
bands, of which the upper two were strongest (lane 1).
Treatment with rapamycin completely shifted 4E-BP1 to the
two fastest migrating species in Rheb-deficient cells, indicative
for de-phosphorylation of the protein (lane 5). In control cells a
fraction of 4E-BP1 remained in the upper band (lane 10),
indicating that phosphorylation of 4E-BP1 is more resistant to
rapamycin treatment compared to Rheb-deficient cells. PP242
treatment increased the mobility of 4E-BP1 in both cell lines
(lanes 2-4 and 7-9). Probing the same lysates with phospho-
specific T37/T46 anti-4E-BP1 antibody showed that PP242
eliminates phosphorylation at T37 and T46 in either cell line,
while rapamycin was much less effective in blocking
phosphorylation of these sites (compare lanes 2-4 with 5 and
7-9 with 10). This is in accordance with earlier publications [38]
[39] [40]. Based on literature [41], we expected the upper band
of 4E-BP1 in Rheb-deficient cells to represent a fraction of 4E-
BP1 phosphorylated at S65 and/or T70. Phospho-specific
antibodies for these sites indeed recognized bands at the
expected size that disappeared following treatment with
rapamycin or PP242. Phosphorylation of 4E-BP1 at T46 is
strongly decreased in Rheb-deficient cells as demonstrated
with a non-phospho-T46-specific antibody. Both rapamycin and
PP242 induced a further increase in the levels of non-phospho-
T46. These data again demonstrate that mTOR activity is
decreased, but not absent, in Rheb-deficient cells compared to
control cells. To rule out that the observed mTORC1 activity
resulted from mutations during the immortalization process, we
generated a second series of Rheb-deficient MEFs starting
with MEFs that were immortalized by expression of SV40 large
T. Also in these cells diminished mTORC1 activity was
detectable as judged from phosphorylation of mTORC1
substrates like S6K and 4E-BP1 (Figure S4a and S4b).
Furthermore, mTORC1 activity could also be induced by serum
and TPA in a rapamycin sensitive manner in these cells (Figure
S4a-c).
Next, we investigated if physiological stimuli would modify
4E-BP1 phosphorylation in Rheb-deficient MEFs. Stimulation of
serum starved Rheb-deficient cells with serum or insulin had
little effect on the motility of 4E-BP1 (Figure 3b, compare lane 1
with 2-3 and lane 8 with 9-10). However, depletion of amino
acids clearly decreased phosphorylation of 4E-BP1 even more
than rapamycin treatment, as judged from the increase in the
fastest migrating 4E-BP1 isoform (lane 4 versus 7 and 11
versus 14 in the 4E-BP1 panel). Add-back of amino acids did
not restore 4E-BP1 phosphorylation (lane 4 versus 5), which is
in line with the observations above that amino acids cannot
rapidly activate mTORC1 in these cells (Figure 1c, lane 3 and
6). On the other hand, serum stimulation did restore
phosphorylation of 4E-BP1 after amino acid deprivation (Figure
3b, lane 4 versus 6). In contrast, 4E-BP1 phosphorylation
occurred in response to both amino acids and serum in wild
type cells (lane 11 versus 12-13).
The phosphorylation status of 4E-BP1 is predictive for its
association with eIF4E, whose activity is blocked by 4E-BP1
binding. Binding of 4E-BP1 to eIF4E was measured by isolating
eIF4E with M7GTP-sepharose beads. In accordance with the
data above, we find that in asynchronously growing Rheb-
negative cells a much larger fraction of 4E-BP1 is associated
with eIF4E than in control cells (Figure 3c, lane 10-12). This
difference is also seen when cells are serum starved (lane 4
versus 1 and 7). Rapamycin increases the fraction of eIF4E-
bound 4E-BP1 in both Rheb positive (lane 5) and negative cell
lines (lane 2 and 8), but the amount is still higher in the latter
cells. Consistent with the more pronounced effect of amino acid
starvation on T37/T46 phosphorylation of 4E-BP1,
downregulation of mTORC1 activity by amino acid depletion
results in more equal levels of eIF4E-bound 4E-BP1 in control
and Rheb-deficient cells (compare lanes 3, 6 and 9). In
summary, we conclude that the absence of Rheb diminishes
4E-BP1 phosphorylation and increases its association with
eIF4E. As seen for other mTOR substrates, residual levels of
phosphorylation are diminished by rapamycin or PP242
treatment. Increased mTORC1 activity is only seen after serum
stimulation, but not following replenishment with amino acids or
stimulation with insulin.
We next wished to delineate the signaling pathway via which
serum can activate mTORC1 in Rheb-deficient cells by using a
panel of pharmacological inhibitors. PI-3 kinase inhibitors like
wortmannin and PI-103 efficiently inhibited mTORC1 (data not
shown). Since we had noticed that serum, in contrast to insulin,
significantly activates ERK in our fibroblasts, we blocked ERK
activation with the MEK inhibitor U0126 (Figure 4a). U0126
clearly reduced T389 phosphorylation of S6K in Rheb-deficient
cells (lane 5 versus 7). In wild type cells, U0126 had barely any
effect (lane 13 versus 15).
Previously, a role for ERK and/or RSK in mTORC1 activation
has been documented, either via inactivation of TSC2 [42][43]
and/or via direct phosphorylation of Raptor [44] [15] [16]. First,
we tested if specific activation of MEK/ERK with TPA could
substitute for serum. Indeed, TPA activated mTORC1 (Figure
4b, lane 1 versus 5) suggesting that MEK/ERK activity is
sufficient.
Since ERK can act upstream of RSK, the effect of the RSK
inhibitor BI-D1870 on S6K phosphorylation by serum was
tested. BI-D1870 had a profound effect on T389
phosphorylation of S6K in Rheb-negative cells (Figure 4c, lane
5 versus 6), indicating that it may be required. In contrast, S6K
mTORC1 Activity in Rheb-Deficient MEFs
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phosphorylation at T389 was largely insensitive to BI-D1870 in
wild type cells (lane 13 versus 14). We noted however, that
S473 phosphorylation of PKB was also affected in serum
starved cells (compare lane 1 with 2 and 9 with 10) or
asynchronously growing cells (data not shown), indicating that
BI-D1870 may target other kinases than RSK. This has also
been reported by others [45][46]. We wondered if genetic
deletion of Rheb woud have the same effect in other cell types.
Figure 3.  Effect of mTOR inhibition on 4E-BP1.  3a. Asynchronously growing cells Rheb-deficient cells (N21) or control cells
(N45) were either left untreated or treated with various concentrations of PP242 (2, 1 or 0.25 µM) or rapamycin (50 nM) for 60
minutes. Total cell lysates were probed with antibodies indicated on the right. 3B. Rheb-deficient cells (N21) or control cells (N45)
were serum starved overnight and stimulated with insulin, serum or rapamycin as indicated on the top. Alternatively cells were
depleted for amino acids for two hours (-AA) after which the culture medium was reconstituted with amino acids (-AA +AA) for 30
minutes or serum (-AA +serum) for 90 minutes. Total lysates were analyzed by Western blot with the antibodies indicated on the
right. 3C. Association of 4E-BP1 with eIF4E from Rheb-deficient (N21, N23) or Rheb-positive (N45) cells. Cells serum starved
overnight and then either treated with rapamycin for 1 hour or depleted for amino acids for two hours. Alternatively, they were grown
in complete medium (lanes 10-12). Subsequently, cells were lysed and eIF4E plus associating proteins were pulled down using an
m7GTP-Sepharose pull-down assay. Isolated proteins (upper two panels) and total lysates (lower three panels) were analyzed by
Western blotting with the antibodies indicated on the right. In all cases the immunoblots shown are representative of observations
for at least two experiments.
doi: 10.1371/journal.pone.0081649.g003
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Figure 4.  Effect of pharmacological inhibitors on mTORC1 activity in Rheb-deficient cells and wild-type cells.  a. Rheb-
deficient (N21) or control cells (N45) were serum starved overnight and treated with U0126 (10 µM), rapamycin (50 nM) or a
combination of both inhibitors for one hour before harvesting. Inhibitors were added 1 hour before serum stimulation. Total lysates
were analyzed by Western blotting with the antibodies indicated on the right. A background band was used as a loading control. 4b.
Effect of TPA on S6K phosphorylation in Rheb-deficient (N21) and control cells (N45). Cells were serum starved overnight and
pretreated with U0126 for 1 hour or not. Cells were stimulated with serum or TPA for 90 or 30 minutes, respectively. Total cell
lysates were analyzed by probing Western blots with the antibodies indicated on the right. 4c. As 4A, but now with the RSK-inhibitor
BI-D1870. In all cases immunoblots shown are representative of observations for at least two experiments. 4d. Small intestinal
organoids with floxed alleles of either Rheb or Tsc1 were grown for seven days after overnight incubation with vehicle or tamoxifen
(4-TOH) as indicated and analyzed for the proteins indicated on the right. 4e. Small intestinal organoids with floxed alleles of either
Rheb (lane 1 to 10) or Tsc1 (lanes 11 to 15) were grown for seven days after overnight incubation with vehicle or tamoxifen (4-TOH)
as indicated and left untreated (lanes 1, 5, 6, 10, 11, 15) or stimulated for 90 minutes with serum. Pretreatment with 50 nm
rapamycin (lanes 3, 5, 8, 10, 13 and 15) or 10 µM U0126 (lanes 4, 9, 14). Numbers on top of immunoblots represent densitometric
ratio of pS6 S235/236 over RalA. Numbers indicate the ratio of pS6K T389 relative to GAPDH in a, b and c and pS6 relative to RalA
in e.
doi: 10.1371/journal.pone.0081649.g004
mTORC1 Activity in Rheb-Deficient MEFs
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To this end, we generated small intestinal organoids from mice
with either a floxed allele of Rheb or TSC1 in combination with
tamoxifen-inducible Cre recombinase [47]. In these organoids,
deletion of Rheb decreased mTORC1 signaling, whereas
TSC1 had the opposite effect (Figure 4d). Serum stimulation of
Rheb-positive and Rheb-negative organoids revealed that loss
of Rheb again lowered, but did not abolish S6 phosphorylation.
Phosphorylation was sensitive to rapamycin, demonstrating the
involvement of mTORC1 (Figure 4e). Also here U0126 had a
profound effect.
In the absence of Rheb, Raptor is a likely entrance point for
stimulatory input on mTORC1. RSK has been reported to
phosphorylate a cluster of conserved sites (S719, S721, S722)
that are recognized by a phospho-PKB-substrate antibody [15].
In addition, ERK has been reported to phosphorylate S863,
which functions as a priming phosphorylation required for
further Raptor phosphorylation [16,44]. We therefore
immunoprecipitated endogenous Raptor from Rheb-negative
cells that had been serum starved. Insulin and serum
stimulation caused a very mild increase in Raptor
phosphorylation as detected with the phospho-PKB-substrate
antibody suggesting that phosphorylation of these sites does
not explain the differential effects on mTORC1 activity by these
stimuli. A very similar pattern of phosphorylation was seen in
Rheb-positive cells (Figure S5, lane 4 versus 5 and 6). S863
phosphorylation of Raptor showed a weak and variable
response following insulin treatment in Rheb-deficient cells
(Figure 5a, lane 2 and 8). In contrast, the effect of serum was
strong and robust in both Rheb-deficient and control cells (lane
3, 6 and 9), consistent with the strong activation of ERK by
serum. This induction was partially inhibited by U0126 (Figure
5b, lane 10-12). Since S863 has also been reported as a direct
target site for mTORC1, we tested the effect of various
inhibitors on serum stimulated S863 phosphorylation. The PKB
inhibitor AKT_VIII only had an inhibitory effect in Rheb-
proficient cells, as would be expected on the basis of the
reported inhibitory action of PKB on TSC2 (Figure 5c, lane 2
versus 5, 7 versus 10 and 12 versus 15). Rapamycin lowered
S863 phosphorylation in both Rheb-negative and -positive cells
(lane 2 versus 3, 7 versus 8 and 12 versus 13). However,
PP242 did not affect phosphorylation of this site in Rheb-
deficient cells (lane 2 versus 4 and 12 versus 14) and only
partially in Rheb-positive cells (lane 7 versus 9), suggesting
that rapamycin may interfere in S863 phosphorylation by
destabilizing mTORC1 rather than by inhibiting mTOR.
Together, these data are consistent with the notion that
phosphorylation of S863 via ERK may contribute to serum
stimulated mTORC1 activity (Figure 5d).
Finally, the physiological relevance of mTOR activity in
Rheb-deficient cells was investigated by studying cell cycle
profiles following overnight treatment with rapamycin of cells
grown in the continuous presence of serum (Figure 6a). A clear
increase in cells in G1 (44 to 62%) was seen in control cells at
the cost of cells in S phase (18 to 10%) and to a lesser extent
M phase (28 to 23%). The proportion of cells in G1 in untreated
Rheb-deficient cells was higher than that of control cells (64
and 54 instead of 44%), but also here a rapamycin-induced
increase was observed (64 to 91% and 54 to 75%). This
change in cell cycle distribution was even more pronounced
when we treated cells with nocodazole so that cycling cells
would accumulate in the G2/M phase, unless they had been
arrested in G1. Under these circumstances a two-fold increase
in G1 was seen in control cells and a threefold increase in
Rheb-deficient cells. Since long-term rapamycin treatment can
affect mTORC2 function [48], we investigated phosphorylation
of PKB by insulin. Both in untreated and rapamycin-treated
cells, a clear induction of S473 of PKB was seen, independent
of the Rheb status of cells (Figure 6b, compare lane 1 with 2
and 6 and lane 7 with 8 and 12). In contrast, overnight
treatment with PP242 interfered in PKB phosphorylation
(compare lane 2 with 4 and 8 with 10). This demonstrates that
the observed cell cycle effect of rapamycin is mediated via
inhibition of mTORC1 and not mTORC2. We used Western
blotting to see if we could identify cell cycle regulators that
were affected by overnight rapamycin treatment. Whereas we
did not observe changes when cell lysates were probed with
antibodies against p27 or p16 (data not shown), a pronounced
decrease in cyclinD1 levels was noticed in Rheb-deficient cells.
Consistent with this observation, phosphorylation of
retinoblastoma decreased more in Rheb-deficient cells as
compared to control cells (Figure 6c). Clearly, these data show
that the remaining mTORC1 activity in Rheb negative cells is
important for cell cycle progression.
Discussion
The current study using Rheb-deficient MEFs confirms
previous studies that Rheb is required for rapid and strong
activation of mTORC1 upon stimulation of serum starved cells
with insulin or amino acid replenishment of amino acid-
deprived cells. Surprisingly, considerable mTORC1 activity is
present in Rheb-deficient cells when grown in serum. A
compensatory role for RhebL1 in mTORC1 activation is highly
unlikely on the basis of our RNAi studies. Also, RhebL1 did not
compensate for Rheb in genetic studies in mice [35].
How can we reconcile mTORC1 activity seen in Rheb-
deficient cells when grown in serum with the lack of mTORC1
signaling following insulin stimulation? In contrast to insulin,
serum activates ERK in our fibroblasts. Blocking ERK or its
downstream target RSK with pharmacological inhibitors
strongly affects the residual mTORC1 activity in Rheb-deficient
cells. Since phosphorylation of Raptor at multiple residues by
RSK [15] or ERK [16] has been shown to positively regulate
mTORC1, we favor a model in which Raptor phosphorylation
by these kinases is sufficient for a basal level of mTORC1 in
the absence of Rheb. In the case of ERK, these sites include
S863 that acts like a priming site required for further
phosphorylation of Raptor. Indeed, we confirm that Raptor is
phosphorylated at S863 by serum stimulation. Intriguingly,
mTOR itself also phosphorylates S863 in vitro and in vivo and
is required for the Rheb-mediated increase of S6K
phosphorylation seen in overexpression studies [17,44]. This is
consistent with our observation that the mTOR inhibitor PP242
affects S863 phosphorylation in Rheb–positive cells, but not in
cells lacking Rheb. Thus, mTORC1 may have a dual input via
Raptor S863 phosphorylation only one of which is Rheb-
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mediated. It should be stressed however, that multiple studies
indicate that the complete phosphorylation pattern of Raptor is
instrumental for mTORC1 activity rather than just S863
phosphorylation. Indeed, since mTORC1 activity is BI-D1870
sensitive, RSK-mediated Raptor phosphorylation is most likely
also required for the basal level of mTORC1 activity in the
absence of Rheb. We think that Rheb-independent mTORC1
activity is not restricted to MEFs given our observations in
small intestinal organoids lacking Rheb and RNAi experiments
in A549 cells. In addition, Fonseca et al. noticed very limited
Figure 5.  Analysis of Raptor phosphorylation.  5a. Rheb-deficient (N21, N23) or control cells (N45) were serum starved
overnight and stimulated for 30 minutes with insulin or 90 minutes with serum. Endogenous Raptor was immuno-precipitated and
Western blots were probed for S863 phosphorylation (upper panel). Hereafter, blots were stripped and probed for total Raptor
levels. A representative example from three experiments is shown. 5b Rheb-deficient (N21, N23) or control cells (N45) were serum
starved overnight and stimulated for 30 minutes with insulin or 90 minutes with serum or pretreated with 10 µM U0126 before serum
stimulation. Endogenous Raptor was immuno-precipitated and Western blots were probed with a pS863 Raptor antibody (upper
panel) and reprobed for Raptor (lower panel). A representative example from two experiments is shown. In all panels numbers
above the blot indicate the ratio of Raptor pS863 relative to Raptor. 5c. Rheb-deficient (N21, N23) or control cells (N45) were serum
starved overnight and either left untreated or stimulated for 90 minutes with serum. Where indicated, cells were pretreated with
rapamycin (50 nM), PP242 (2 µM) or the PKB-inhibitor AKT_VIII (10 µM) for 60 minutes. Hereafter, endogenous Raptor was
immuno-precipitated and analyzed under 5a. The immunoblots shown are representative of observations for at least two
experiments. A representative example from two experiments is shown. 5d. Schematic representation of the mechanism of Rheb-
independent mTORC1 activation. Arrows represent activation, squares indicate inhibition.
doi: 10.1371/journal.pone.0081649.g005
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Figure 6.  Effect of Rapamycin on cell cycle profile of Rheb-deficient (N21, N23) or control cells (N45).  6a. Cells were grown
in the absence or presence of 50 nM rapamycin, 250 ng/ml nocodazole or a combination thereof for 18 hours. Cell cycle profiles
were determined as described under methods. The cell cycle profiles shown are representative of observations for two experiments.
6b. Rheb-deficient (N23) or control cells (N45) were grown overnight in the presence of 1.0 µM PP242 or 50 nM rapamycin on
mTORC2 activity. Subsequently, cells were stimulated with insulin for 30 minutes and total lysates were analyzed by Western
blotting using the antibodies indicated on the right. The immunoblots shown are representative of observations for two experiments.
6c. Rheb-deficient (N21, N23) or control cells (N45) were grown overnight in the presence of 50 nM rapamycin or were serum
starved for 24 hours. Total lysates were analyzed by Western blotting using the antibodies indicated on the right. The immunoblots
shown are representative for two experiments. Numbers on top represent the densitometic ratio of cyclin D1 over RalA.
doi: 10.1371/journal.pone.0081649.g006
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TSC2 phosphorylation during TPA-induced mTORC1 activation
in HEK293 cells and suggested the existence of a TSC2-
independent mechanism [46].
The molecular mechanism via which Rheb activates
mTORC1 is still incompletely understood. From in vitro mTOR
kinase assays it is clear that the association of Rheb with
mTORC1 is not required for mTOR to be active. Rheb is not
present in detectable amounts in immunoprecipitates used for
mTOR kinase assays due to its low affinity for mTOR ([20], our
unpublished observations). Rheb may activate mTOR kinase
activity via direct binding [49] and this effect has been
mimicked in in vitro mTORC1 kinase assays [20,50].
Alternatively, Rheb may enhance substrate binding to
mTORC1, which is supported both by in vivo [51,52] and in
vitro [53] evidence. Finally, Rheb may compete with mTORC1-
inhibitory proteins like PRAS40 [19] [20] or possibly FKBP38
[54] [50] [53]. Unfortunately, we and others have not yet been
able to find a specific effect of GTP-bound Rheb in in vitro
mTORC1 assays (data not shown; see also 52).
The fact that amino acid depletion has a profound effect on
mTORC1 activity in Rheb-deficient cells seems at odds with
the prevalent model of regulation of mTORC1 by amino acids.
In this model, dimeric Rag GTPases are activated by amino
acids and target mTORC1 from the cytoplasm to lysosomes
where Rheb is localized [55] [25] [24]. Apparently, a parallel
system operates to downregulate mTORC1 when cells are
starved for amino acids. One option is that mTORC1
downregulation by amino acids involves activation of
phosphatase PP2A by association with PR61ε, leading to
dephosphorylation of MAP4K3 [56]. Alternatively, decreased
activity of the class III PI-3 kinase VPS34 underlies the effect of
amino acid depletion in Rheb-deficient cells. VPS34 produces
PtdIns(3)P in an amino acid-dependent manner [23] [57].
Recently, PtdIns(3)P generated by VPS34 was shown to target
PLD1 to lysosomes, where local production of phosphatidic
acid could activate mTOR [58]. Interestingly, VPS34 negative
MEFs resemble our Rheb deficient MEFs in that they do not
acutely increase mTORC1 activity upon amino acid stimulation.
Furthermore, when grown in the presence of serum VPS34
negative MEFs have normal levels of mTORC1 activity [59],
demonstrating that the requirement for upstream activators of
mTORC1 is dependent on the precise nature of the stimulus.
The TSC/Rheb/mTORC1 pathway is essential for rapidly
adapting cellular and organismal metabolism to changes in
nutrients and growth factors (e.g. [29] [60]). In addition, this
pathway functions in myelination of the brain [35]. We
demonstrate here a role for Rheb-independent mTORC1
activity in cell cycle progression under normal growth
conditions. mTOR-mediated cell proliferation in MEFs is known
to depend on repressing 4E-BPs [4]. The decreased mTOR
activity in Rheb-deficient cells results in a significant increase in
non-phosphorylated 4E-BP1 and a concomitant increase in the
fraction of eIF4E-associated 4E-BP1. Remarkably, this has no
major impact on cell proliferation since growth rates do not
differ significantly between Rheb-negative and control cells.
Rapamycin further increases non-phosphorylated 4E-BP1 and
this correlates with an increase in cells in the G1-phase of the
cell cycle. This results in a decreased expression level of cyclin
D1 and diminished phosphorylation of retinoblastoma,
especially in Rheb-deficient cells. A similar effect of rapamycin
has previously been described [61] Since deletion of Rheb
results in embryonic lethality in mid-gestation, which is much
later than seen after disruption of another mTORC1-specific
protein, Raptor [33], it is reasonable to assume that also during
early embryogenesis mTORC1 is partially active in the
absence of Rheb to drive cell cycle progression. This may
seem implausible in light of all studies focusing on insulin-
mediated mTORC1 activity, but is less surprising from an
evolutionary point of view. Our previous evolutionary analysis
of the mTOR pathway showed that Rheb was most likely
present in the last eukaryotic common ancestor. However,
during the emergence of e.g. green plants and algae Rheb has
been lost, while mTORC1 proteins were conserved [26]. It will
be interesting to see what the exact mode of activation is in
species that contain mTORC1 proteins, but no Rheb.
Material and Methods
Ethics statement
All experiments were approved by the local ethical
committee for animal research (Dier Experimentele Commissie
(DEC) Erasmus MC; Approval EMC 2467) and were in
accordance with the institutional animal care and use
committee guidelines.
Antibodies and inhibitors
anti-phospho-T389-S6K, anti-phospho-S235/236-S6, anti-
RAPTOR, anti-mTOR, anti-PRAS40, anti-phospho-S473-PKB,
anti-S6K, anti-4EBP1, anti-phospho-T37/46-4EBP1, anti- non-
phospho-T46-4EBP1, anti-phospho-ERK1/2, anti-pAMPK
T172, anti-eIF4E and anti-IRS-1 were from Cell Signaling; anti-
phospho-PRAS40 S183 from IBL-America; anti-phospho-T246-
PRAS40 from Invitrogen BioSource; anti-Raptor was from the
University of Dundee (J. Hastie), anti-PKB was home-made;
anti-GAPDH and anti-phospho-Raptor S863 were from Santa
Cruz; anti-Rheb was a monoclonal antibody generated by R.F.
Lamb; anti-LAMP1 was a kind gift from Peter van der Sluijs.
Rapamycin was purchased from ENZO Life Sciences,
UO126 from Promega, BI-D1870 from Axon Medchem and
PP242 and AKT_VIII from Sigma Aldrich.
Cell lines, tissue culture and transfections
To obtain MEFs, 13 day pregnant homozygously floxed
Rheb mice in C57Bl/6 background [34] were decapitated under
deep isoflurane anesthesia and the embryos were isolated to
obtain MEFs. Spontaneously immortalized or large T
immortalized MEFs with a floxed Rheb allele were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% FCS, 4 mM L-glutamine and pen/strep at 37 °C with
5% CO2. MEFs were infected with Ad-CMV-Cre adenovirus
(Vector-Biolabs) in the presence of 4 μg/ml polybrene added to
a 1:1 mixture of fresh medium and medium conditioned by wild
type MEFs. Two days after infections cells were grown for two
passages on fibronectin-coated dishes. Hereafter Rheb-
negative, monoclonal cell lines were obtained by serial dilution
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in 96 well plates. A549 cells were grown in RPMI
supplemented with 10% FCS, 4 mM L-glutamine and pen/strep
at 37 °C with 5% CO2. Stimulation of cells was done after
overnight serum starvation, eventually followed by amino acid
depletion for two hours in custom-made amino acid free DMEM
(Gibco Life Technologies). Serum stimulation was done with
10% fetal calf serum, final concentrations for insulin and TPA
were 5 μg/ml and 100ng/ml, respectively. Stimulation with
amino acids was done supplementing cells with the normal
concentration of essential amino acids. Cells were pretreated
with inhibitors for 60 minutes unless otherwise indicated.
Concentrations used were: rapamycin (50 nM), UO126 and BI-
D1870 (10 μM), PP242 as indicated. siRNA transfections were
performed 72 and 48 hours before experiments with 50 nM
ON-TARGETplus SMARTpools (Dharmacon Inc.) targeting
indicated genes using Oligofectamine (Invitrogen). Small
intestinal organoids were grown from Rhebf/f::Cag-CreERT+
and Tsc1f/f::Cag-CreERT+ [47] mice as described in [62].
Excision of respectively Rheb and TSC1 was induced by over-
night treatment with tamoxifen. Seven days later, organoids
were treated as indicated in the figure legends, washed in ice
cold PBS and lysed in Laemmli sample buffer.
Cell lysates and immunoblotting
In all cases, cells were washed twice with ice cold PBS
before scraping them in 1x Laemmli sample buffer. Western
blotting was done using PVDF membrane. Blots were
quantified with ImageJ.
7-methyl GTP-Sepharose pull-downs
7-Methyl GTP-Sepharose beads (GE Healthcare UK Limited;
15 μl/sample) were washed three times in M7-Lysis Buffer (100
mM KCl, 5 mM MgCl2, 0.5% TX-100, 20 mM Tris HCl (pH 7.5),
10% glycerol, 10 mM NaF, 1 mM Na2VO4 0.1 µM Aprotinin and
1 µM Leupeptin). Cells were washed twice with cold PBS and
lysed in M7-Lysis Buffer. After spinning at 4 °C, 14000 rpm for
10 minutes, Part of the lysate was mixed with a quarter volume
5x LSB. The rest was tumbled with beads for 45-60 minutes at
4 °C, washed 4 times with M7-Lysis Buffer and mixed with 40
μl of 1x LSB.
Quantitative real-time PCR
Expression of Rheb and RhebL1 mRNA was examined by
reverse transcription of total RNA followed by real-time
quantitative PCR on an ABI cycler using SYBR Green (ABI)
and the oligonucleotides 5′-TACCGGTCTGTGGGAAAGTC-3′
(in exon 2), 5′-GCCCCGCTGTGTCTACAA-3′ (in exon 3) and
5′-TCCCCACCATATCCAACAAC-3′ (in exon 5) for Rheb and
the oligonucleotides 5′-ACTCGTGTGCTATGCCACTG-3′ and
5′-GCGCAGAGAGTTAACCGAGT-3′ for RhebL1.
FACS analysis
Cells were grown to 90% confluency and following
trypsinization resuspended in medium collected from the
corresponding plates. Following centrifugation (5’, 1200rpm),
cells were washed once with PBS, resuspended in 300 μl PBS
and 700μl 70% ethanol. After incubation at -20 °C for 45
minutes, cells were spun (5’, 1500 rpm) and resuspended in
500 μl PBS with 40 μg/ml Propidium Iodide and 10 μg/ml
RNase. Following incubation at room temperature for 30
minutes in the dark, cell cycle analysis was performed on a BD
FACSCalibur.
Immunofluorescence
MEFs were grown to confluency on glass coverslips and
given fresh medium 16 hrs before fixation with 4%
formaldehyde for 20 min. Cells were permeabilized with 0.25%
Saponin for 10 minutes, blocked with 10% FCS in PBS with
0.25% Saponin for 30 minutes and incubated overnight with
primary antibodies in PBS with 0.25% Saponin and 1% FCS.
Incubation with secondary antibody in PBS with 0.25% Saponin
and 1% FCS was done for 1 hour, and DAPI for 5 minutes.
After washing cells were mounted and examined on a Zeiss
Axioskop2 LSM510 confocal microscope.
Statistics
Data are expressed as means ± st. dev. Significance was
assessed by unpaired t-test in IBM SPSS Statistics 20
(Armonk, NY, USA). P-values less than 0.05 were considered
as significant.
Supporting Information
Figure S1.  Demonstration of complete absence of
functional Rheb. S1a Effect of short term infection of MEFs
with a floxed allele of Rheb with Ad-CMV-Cre adenovirus. Total
cell lysates were made of MEFs 96 hours after infection with
increasing amounts of adenovirus in the presence of 2 or 4 mg
polybrene/ml as indicated. Lysates were analyzed by Western
blotting with the indicated antibodies. S1b Agarose gel with
products of Q-PCR for Rheb mRNA from control cells (N45;
lane 2 and 4) and Rheb-deficient (N23; lane 1 and 3) cells
using primers from exon 2 and 3 (lane 1 and 2) or from exon 2
and 5 (lane 3 and 4). S1c Predicted truncated Rheb protein
based on sequences of Q-PCR products from 1b, which
matches prediction of targeting construct. Western blots of total
cell lysates from Rheb-deficient cell lines (N21, N23) or Rheb-
containing control cells (N45) probed with antibodies against
proteins indicated.
(TIF)
Figure S2.  Localization of mTOR, Rheb and LAMP1 under
various conditions in control and Rheb-deficient cells. S2a
Immunofluorescence of localization of mTOR (red), LAMP1
(green) or co-localization of both (merge, yellow) in control
(N45) and Rheb-negative cells (N23) grown in the continuous
presence of serum. S2b Quantification of the relative co-
localization of mTOR and LAMP1 in control (N45) and Rheb-
deficient (N23) cells as shown in Figure S2a.
Immunofluorescence intensity was thresholded in Image-J and
co-localization indices were determined with the following
plugin; http://www.mbs.med.kyoto-u.ac.jp/imagej/index.html.
S2c. Immunofluorescence of localization of Rheb (red), in
control (N45, L12) and Rheb-negative cells (N23, L10) grown in
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the continuous presence of serum. S2d. Immunofluorescence
of localization of mTOR (red), LAMP1 (green) or co-localization
of both (merge, yellow) in control (N45) and Rheb-negative
cells (N21) either starved for amino acids (-AA, top panel) or
stimulated with amino acids (-AA+AA, bottom panel). S2e.
Immunofluorescence of localization of mTOR (red), LAMP1
(green) or co-localization of both (merge, yellow) in control
(N45) and Rheb-negative cells (N23) either serum starved (ss,
top panel) or stimulated with insulin (+ins, bottom panel).
(TIF)
Figure S3.  Effect of energy stress and RhebL1 RNAi on
the T389 phosphorylation in control and Rheb-deficient
cells. S3a. Cells kept in the presence of serum were treated
with the agents indicated. Western blots with total lysates were
probed with the antibodies indicated on the right. A
representative example of two experiments is shown. Numbers
on top of immunoblots indicate ratio Raptor S792 relative to
Raptor. S3b. Western blot of total cell lysates from dishes that
had been transfected with the indicated siRNA of Rheb-/- (N23)
and Rheb+/+ (N45) cells. A representative example of two
experiments is shown. Numbers on top of immunoblots indicate
intensity of pS6K T389 relative to GAPDH. S3c. Quantification
of the levels of RhebL1 RNA in Rheb-/- (N23) and Rheb+/+
(N45) cells as determined by Q-PCR. These were duplicates of
the cells used in Figure S2b. S3d. Western blot of total cell
lysates from dishes of A549 cells that had been transfected
with the indicated siRNAs and either serum starved o/n,
stimulated with insulin for 20 minutes, or grown in the
continuous presence of serum (CS). Representative
immmunoblots from two experiments are shown.
(TIF)
Figure S4.  Analysis of mTORC1 signalling under various
conditions in Large T immortalized control and Rheb-
deficient cells. S4a. Large T immortalized MEFs that were
either Rheb-deficient (L1, L10) or control cells (L12) were
grown in the continuous presence of serum (CS), serum
starved o/n (SS) and re-stimulated with either serum for 90
minutes (+S, 90’) or insulin for 20 minutes (+ins, 20’). S4b.
Analysis of mTORC1 activity by Western blotting in total
lysates of large T immortalized MEFs that were either Rheb-
deficient (L1, L10) or control cells (L5). Cells were serum
starved overnight and left untreated, stimulated with insulin for
30 minutes (Ins) or depleted for amino acids for two hours and
then replenished with amino acids for 30 minutes (AA). S4c.
Large T immortalized MEFs that were either Rheb-deficient
(L10; upper panels) or control cells (L12; lower panels) were
grown in the continuous presence of serum (CS), serum
starved o/n (SS) and re-stimulated with either serum for 90
minutes (+S) or TPA for 90 minutes (TPA). Cells were treated
with rapamycin (50 nM) for one hour before harvesting.
Western blots of total cell lysates were probed with antibodies
against proteins indicated. In all cases Western blots shown
are representative for two experiments.
(TIF)
Figure S5.  Effect of insulin and serum stimulation on
Raptor phosphorylation. Rheb-deficient (N23) or control cells
(N45) were serum starved overnight and stimulated for 30
minutes with insulin or 90 minutes with serum. Endogenous
Raptor was immuno-precipitated and Western blots were
probed with a phospo-PKB-substrate antibody (upper panel).
Hereafter, blots were stripped and reprobed for total Raptor
levels. A representative example of two experiments is shown.
Numbers on top of immunoblots indicate ratio Raptor over
pPKB substrate. Immunoblots are representative for two
experiments.
(TIF)
Acknowledgements
We would like to thank M. Nellist and M. Hoogeveen-
Westerveld for their technical assistance. We would like to
thank Hugo Snippert and Ingrid Verlaan-Klink for help with
growing organoids.
Author Contributions
Conceived and designed the experiments: MJG FJTZ.
Performed the experiments: MJG SMIG JK WPvB FJTZ RFL.
Analyzed the data: MJG FJTZ SMIG YE RFL. Contributed
reagents/materials/analysis tools: SMIG YE RFL. Wrote the
manuscript: MJG FJTZ.
References
1. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal
integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12:
21-35. doi:10.1038/nrm3025. PubMed: 21157483.
2. Avruch J, Hara K, Lin Y, Liu M, Long X et al. (2006) Insulin and amino-
acid regulation of mTOR signaling and kinase activity through the Rheb
GTPase. Oncogene 25: 6361-6372. doi:10.1038/sj.onc.1209882.
PubMed: 17041622.
3. Ma XM, Blenis J (2009) Molecular mechanisms of mTOR-mediated
translational control. Nat Rev Mol Cell Biol 10: 307-318. doi:10.1038/
nrm2672. PubMed: 19339977.
4. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD et al.
(2011) mTORC1-mediated cell proliferation, but not cell growth,
controlled by the 4E-BPs. Science 328: 1172-1176.
5. Saucedo LJ, Gao X, Chiarelli DA, Li L, Pan D et al. (2003) Rheb
promotes cell growth as a component of the insulin/TOR signalling
network. Nat Cell Biol 5: 566-571. doi:10.1038/ncb996. PubMed:
12766776.
6. Stocker H, Radimerski T, Schindelholz B, Wittwer F, Belawat P et al.
(2003) Rheb is an essential regulator of S6K in controlling cell growth in
Drosophila. Nat Cell Biol 5: 559-565. doi:10.1038/ncb995. PubMed:
12766775.
7. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002)
Identification of the tuberous sclerosis complex-2 tumor suppressor
gene product tuberin as a target of the phosphoinositide 3-kinase/akt
pathway. Mol Cell 10: 151-162. doi:10.1016/S1097-2765(02)00568-3.
PubMed: 12150915.
8. Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated
and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:
648-657. doi:10.1038/ncb839. PubMed: 12172553.
9. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL (2004)
Regulation of the TSC pathway by LKB1: evidence of a molecular link
between tuberous sclerosis complex and Peutz-Jeghers syndrome.
Genes Dev 18: 1533-1538. doi:10.1101/gad.1199104. PubMed:
15231735.
mTORC1 Activity in Rheb-Deficient MEFs
PLOS ONE | www.plosone.org 13 November 2013 | Volume 8 | Issue 11 | e81649
10. Kwiatkowski DJ, Manning BD (2005) Tuberous sclerosis: a GAP at the
crossroads of multiple signaling pathways. Hum Mol Genet 14 spec No.
2: R251-R258. PubMed: 16244323.
11. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M et al.
(2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP
signaling, is inhibited by TSC1 and 2. Mol Cell 11: 1457-1466. doi:
10.1016/S1097-2765(03)00220-X. PubMed: 12820960.
12. Schalm SS, Blenis J (2002) Identification of a conserved motif required
for mTOR signaling. Curr Biol 12: 632-639. doi:10.1016/
S0960-9822(02)00762-5. PubMed: 11967149.
13. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR et al. (2002) mTOR
interacts with raptor to form a nutrient-sensitive complex that signals to
the cell growth machinery. Cell 110: 163-175. doi:10.1016/
S0092-8674(02)00808-5. PubMed: 12150925.
14. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A et al.
(2008) AMPK phosphorylation of raptor mediates a metabolic
checkpoint. Mol Cell 30: 214-226. doi:10.1016/j.molcel.2008.03.003.
PubMed: 18439900.
15. Carrière A, Cargnello M, Julien LA, Gao H, Bonneil E et al. (2008)
Oncogenic MAPK signaling stimulates mTORC1 activity by promoting
RSK-mediated raptor phosphorylation. Curr Biol 18: 1269-1277. doi:
10.1016/j.cub.2008.07.078. PubMed: 18722121.
16. Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonneil E et al.
(2011) ERK1/2 phosphorylate Raptor to promote Ras-dependent
activation of mTOR complex 1 (mTORC1). J Biol Chem 286: 567-577.
doi:10.1074/jbc.M110.159046. PubMed: 21071439.
17. Wang L, Lawrence JC Jr., Sturgill TW, Harris TE (2009) Mammalian
target of rapamycin complex 1 (mTORC1) activity is associated with
phosphorylation of raptor by mTOR. J Biol Chem 284: 14693-14697.
doi:10.1074/jbc.C109.002907. PubMed: 19346248.
18. Foster KG, Acosta-Jaquez HA, Romeo Y, Ekim B, Soliman GA et al.
(2010) Regulation of mTOR complex 1 (mTORC1) by raptor Ser863
and multisite phosphorylation. J Biol Chem 285: 80-94. PubMed:
19864431.
19. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH (2007)
Insulin signalling to mTOR mediated by the Akt/PKB substrate
PRAS40. Nat Cell Biol 9: 316-323. doi:10.1038/ncb1547. PubMed:
17277771.
20. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA et al.
(2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein
kinase. Mol Cell 25: 903-915. doi:10.1016/j.molcel.2007.03.003.
PubMed: 17386266.
21. Oshiro N, Takahashi R, Yoshino K, Tanimura K, Nakashima A et al.
(2007) The proline-rich Akt substrate of 40 kDa (PRAS40) is a
physiological substrate of mammalian target of rapamycin complex 1. J
Biol Chem 282: 20329-20339. doi:10.1074/jbc.M702636200. PubMed:
17517883.
22. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C et al. (1998)
Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E
BP1 through a common effector mechanism. J Biol Chem 273:
14484-14494. doi:10.1074/jbc.273.23.14484. PubMed: 9603962.
23. Nobukuni T, Joaquin M, Roccio M, Dann SG, Kim SY et al. (2005)
Amino acids mediate mTOR/raptor signaling through activation of class
3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A 102:
14238-14243. doi:10.1073/pnas.0506925102. PubMed: 16176982.
24. Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL (2008)
Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell
Biol 10: 935-945. doi:10.1038/ncb1753. PubMed: 18604198.
25. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC et al.
(2008) The Rag GTPases bind raptor and mediate amino acid signaling
to mTORC1. Science 320: 1496-1501. doi:10.1126/science.1157535.
PubMed: 18497260.
26. van Dam TJ, Zwartkruis FJ, Bos JL, Snel B (2011) Evolution of the
TOR Pathway. J Mol Evol, 73: 209–20. PubMed: 22057117.
27. Soulard A, Cohen A, Hall MN (2009) TOR signaling in invertebrates.
Curr Opin Cell Biol 21: 825-836. doi:10.1016/j.ceb.2009.08.007.
PubMed: 19767189.
28. Aguilar V, Alliouachene S, Sotiropoulos A, Sobering A, Athea Y et al.
(2007) S6 kinase deletion suppresses muscle growth adaptations to
nutrient availability by activating AMP kinase. Cell Metab 5: 476-487.
doi:10.1016/j.cmet.2007.05.006. PubMed: 17550782.
29. Sengupta S, Peterson TR, Laplante M, Oh S, Sabatini DM (2010)
mTORC1 controls fasting-induced ketogenesis and its modulation by
ageing. Nature 468: 1100-1104. doi:10.1038/nature09584. PubMed:
21179166.
30. Polak P, Cybulski N, Feige JN, Auwerx J, Rüegg MA et al. (2008)
Adipose-specific knockout of raptor results in lean mice with enhanced
mitochondrial respiration. Cell Metab 8: 399-410. doi:10.1016/j.cmet.
2008.09.003. PubMed: 19046571.
31. Gangloff YG, Mueller M, Dann SG, Svoboda P, Sticker M et al. (2004)
Disruption of the mouse mTOR gene leads to early postimplantation
lethality and prohibits embryonic stem cell development. Mol Cell Biol
24: 9508-9516. doi:10.1128/MCB.24.21.9508-9516.2004. PubMed:
15485918.
32. Murakami M, Ichisaka T, Maeda M, Oshiro N, Hara K et al. (2004)
mTOR is essential for growth and proliferation in early mouse embryos
and embryonic stem cells. Mol Cell Biol 24: 6710-6718. doi:10.1128/
MCB.24.15.6710-6718.2004. PubMed: 15254238.
33. Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY et al.
(2006) Ablation in mice of the mTORC components raptor, rictor, or
mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO
and PKCalpha, but not S6K1. Dev Cell 11: 859-871. doi:10.1016/
j.devcel.2006.10.007. PubMed: 17141160.
34. Goorden SM, Hoogeveen-Westerveld M, Cheng C, van Woerden GM,
Mozaffari M et al. (2011) Rheb is essential for murine development. Mol
Cell Biol 31: 1672-1678. doi:10.1128/MCB.00985-10. PubMed:
21321084.
35. Zou J, Zhou L, Du XX, Ji Y, Xu J et al. (2011) Rheb1 is required for
mTORC1 and myelination in postnatal brain development. Dev Cell 20:
97-108. doi:10.1016/j.devcel.2010.11.020. PubMed: 21238928.
36. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M et al. (2004)
Absence of S6K1 protects against age- and diet-induced obesity while
enhancing insulin sensitivity. Nature 431: 200-205. doi:10.1038/
nature02866. PubMed: 15306821.
37. Tee AR, Blenis J, Proud CG (2005) Analysis of mTOR signaling by the
small G-proteins, Rheb and RhebL1. FEBS Lett 579: 4763-4768. doi:
10.1016/j.febslet.2005.07.054. PubMed: 16098514.
38. Gingras AC, Gygi SP, Raught B, Polakiewicz RD, Abraham RT et al.
(1999) Regulation of 4E-BP1 phosphorylation: a novel two-step
mechanism. Genes Dev 13: 1422-1437. doi:10.1101/gad.13.11.1422.
PubMed: 10364159.
39. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J et al. (2009) An
ATP-competitive mammalian target of rapamycin inhibitor reveals
rapamycin-resistant functions of mTORC1. J Biol Chem 284:
8023-8032. doi:10.1074/jbc.M900301200. PubMed: 19150980.
40. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J (2008) Rapamycin
differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific
repression of mRNA translation. Proc Natl Acad Sci U S A 105:
17414-17419. doi:10.1073/pnas.0809136105. PubMed: 18955708.
41. Wang X, Beugnet A, Murakami M, Yamanaka S, Proud CG (2005)
Distinct signaling events downstream of mTOR cooperate to mediate
the effects of amino acids and insulin on initiation factor 4E-binding
proteins. Mol Cell Biol 25: 2558-2572. doi:10.1128/MCB.
25.7.2558-2572.2005. PubMed: 15767663.
42. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004) Tumor-
promoting phorbol esters and activated Ras inactivate the tuberous
sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc
Natl Acad Sci U S A 101: 13489-13494. doi:10.1073/pnas.0405659101.
PubMed: 15342917.
43. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005)
Phosphorylation and functional inactivation of TSC2 by Erk implications
for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193. doi:
10.1016/j.cell.2005.02.031. PubMed: 15851026.
44. Foster KG, Acosta-Jaquez HA, Romeo Y, Ekim B, Soliman GA et al.
(2010) Regulation of mTOR complex 1 (mTORC1) by raptor Ser863
and multisite phosphorylation. J Biol Chem 285: 80-94. doi:10.1074/
jbc.M109.029637. PubMed: 19864431.
45. Chen S, Mackintosh C (2009) Differential regulation of NHE1
phosphorylation and glucose uptake by inhibitors of the ERK pathway
and p90RSK in 3T3-L1 adipocytes. Cell Signal 21: 1984-1993. doi:
10.1016/j.cellsig.2009.09.009. PubMed: 19765648.
46. Fonseca BD, Alain T, Finestone LK, Huang BP, Rolfe M et al. (2011)
Pharmacological and genetic evaluation of proposed roles of mitogen-
activated protein kinase/extracellular signal-regulated kinase kinase
(MEK), extracellular signal-regulated kinase (ERK), and p90(RSK) in
the control of mTORC1 protein signaling by phorbol esters. J Biol
Chem 286: 27111-27122. doi:10.1074/jbc.M111.260794. PubMed:
21659537.
47. Abs E, Goorden SM, Schreiber J, Overwater IE, Hoogeveen-
Westerveld M et al. (2013) TORC1-dependent epilepsy caused by
acute biallelic Tsc1 deletion in adult mice. Ann Neurol: ([MedlinePgn:])
PubMed: 23720219.
48. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP et al. (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/
PKB. Mol Cell 22: 159-168. doi:10.1016/j.molcel.2006.03.029. PubMed:
16603397.
mTORC1 Activity in Rheb-Deficient MEFs
PLOS ONE | www.plosone.org 14 November 2013 | Volume 8 | Issue 11 | e81649
49. Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J (2005) Rheb binds
and regulates the mTOR kinase. Curr Biol 15: 702-713. doi:10.1016/
j.cub.2005.02.053. PubMed: 15854902.
50. Dunlop EA, Dodd KM, Seymour LA, Tee AR (2009) Mammalian target
of rapamycin complex 1-mediated phosphorylation of eukaryotic
initiation factor 4E-binding protein 1 requires multiple protein-protein
interactions for substrate recognition. Cell Signal 21: 1073-1084. doi:
10.1016/j.cellsig.2009.02.024. PubMed: 19272448.
51. Wang L, Rhodes CJ, Lawrence JC Jr. (2006) Activation of mammalian
target of rapamycin (mTOR) by insulin is associated with stimulation of
4EBP1 binding to dimeric mTOR complex 1. J Biol Chem 281:
24293-24303. doi:10.1074/jbc.M603566200. PubMed: 16798736.
52. Rapley J, Oshiro N, Ortiz-Vega S, Avruch J (2011) The mechanism of
insulin-stimulated 4E-BP protein binding to mammalian target of
rapamycin (mTOR) complex 1 and its contribution to mTOR complex 1
signaling. J Biol Chem 286: 38043-38053. doi:10.1074/
jbc.M111.245449. PubMed: 21914810.
53. Sato T, Nakashima A, Guo L, Tamanoi F (2009) Specific activation of
mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of
its substrate protein. J Biol Chem 284: 12783-12791. doi:10.1074/
jbc.M809207200. PubMed: 19299511.
54. Bai X, Ma D, Liu A, Shen X, Wang QJ et al. (2007) Rheb activates
mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318:
977-980. doi:10.1126/science.1147379. PubMed: 17991864.
55. Sancak Y, Bar-Peled L, Zoncu R, Markhard AL, Nada S et al. (2010)
Ragulator-Rag complex targets mTORC1 to the lysosomal surface and
is necessary for its activation by amino acids. Cell 141: 290-303. doi:
10.1016/j.cell.2010.02.024. PubMed: 20381137.
56. Yan L, Mieulet V, Burgess D, Findlay GM, Sully K et al. (2010) PP2A
T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR.
Mol Cell 37: 633-642. doi:10.1016/j.molcel.2010.01.031. PubMed:
20227368.
57. Xu L, Salloum D, Medlin PS, Saqcena M, Yellen P et al. (2011)
Phospholipase D mediates nutrient input to mammalian target of
rapamycin complex 1 (mTORC1). J Biol Chem 286: 25477-25486. doi:
10.1074/jbc.M111.249631. PubMed: 21622984.
58. Yoon MS, Du G, Backer JM, Frohman MA, Chen J (2011) Class III
PI-3-kinase activates phospholipase D in an amino acid-sensing
mTORC1 pathway. J Cell Biol 195: 435-447. doi:10.1083/jcb.
201107033. PubMed: 22024166.
59. Jaber N, Dou Z, Lin RZ, Zhang J, Zong WX (2012) Mammalian
PIK3C3/VPS34: the key to autophagic processing in liver and heart.
Autophagy 8: 707-708. doi:10.4161/auto.19627. PubMed: 22498475.
60. Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H et al. (2010)
Glucose addiction of TSC null cells is caused by failed mTORC1-
dependent balancing of metabolic demand with supply. Mol Cell 38:
487-499. doi:10.1016/j.molcel.2010.05.007. PubMed: 20513425.
61. Hidalgo M, Rowinsky EK (2000) The rapamycin-sensitive signal
transduction pathway as a target for cancer therapy. Oncogene 19:
6680-6686. doi:10.1038/sj.onc.1204091. PubMed: 11426655.
62. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N et al.
(2009) Single Lgr5 stem cells build crypt-villus structures in vitro without
a mesenchymal niche. Nature 459: 262-265. doi:10.1038/nature07935.
PubMed: 19329995.
mTORC1 Activity in Rheb-Deficient MEFs
PLOS ONE | www.plosone.org 15 November 2013 | Volume 8 | Issue 11 | e81649
